Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172374 · ClinicalTrials.gov registry record
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
A clinical trial of Primary Ciliary Dyskinesia, sponsored by ReCode Therapeutics.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT06172374: Active study of Primary Ciliary Dyskinesia, sponsored by ReCode Therapeutics.
NCT06172374 is a study of Primary Ciliary Dyskinesia that is active but no longer recruiting, run by ReCode Therapeutics. The registered enrollment target is 150 participants, above the 89-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06172374, a study of Primary Ciliary Dyskinesia, is active but no longer recruiting, sponsored by ReCode Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.
Primary Outcome
Number of individuals with DNAI1 will be measured by tracking amount of completed questionnaires eligible for genetic testing resulting with DNAI1 gene mutation
Conditions Studied
Interventions
- GENETIC Sano Genetics Testing Kit
Study Locations (1)
California
- ReCode Therapeutics, Inc. - Menlo Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2025-12 |
What the registry record for NCT06172374 still lists
NCT06172374 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 89-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (69% higher).
The record links to 1 condition, with Primary Ciliary Dyskinesia appearing as the primary indexed condition, and to 1 intervention - of which Sano Genetics Testing Kit is the first listed.
NCT06172374 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06172374 about?
NCT06172374 is a clinical study titled "A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials". Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.
What is the current status of trial NCT06172374?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2023-08-31. Estimated completion is 2025-12.
What conditions does trial NCT06172374 study?
This clinical trial studies the following conditions: Primary Ciliary Dyskinesia.
What interventions are being tested in trial NCT06172374?
The interventions under investigation include: Sano Genetics Testing Kit (GENETIC).
Who is sponsoring clinical trial NCT06172374?
This trial is sponsored by ReCode Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172374 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Ciliary Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care
RECRUITING
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING · NA
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING
-
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
ACTIVE NOT RECRUITING
-
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI